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ESSAY: PHARMACEUTICALS AND GLOBAL JUSTICE: BALANCING PUBLIC HEALTH

AND INTELLECTUAL PROPERTY RIGHTS
by Marisa Morabito

I. INTRODUCTION
Patents and prices have had a detrimental impact on poverty and the spread

such as HIV/AIDS which remains a significant issue globally, especially

Hopkins states "The Agreement on Trade Related Aspects

of

in

of diseases

South Africa.

Intellectual Property Rights

(TRIPS), govemed by the World Trade Organization, provides for stringent patent protection in
the name of intellectual property rights. This international agreement has elicited public health
concerns in developing countries, worried that they

will be unable to access essential medicines

as a result of increasing patented drug costs."l According to statistics from the Just Like My

Child Foundation, HIV/AIDs in Africa are great in number.2 Statistics show that "to date,

17

million Africans have died of AIDS and 25 million Africans (many children) are infected with
the HIV virus. HIV can be treated with modern medications, so long as those drugs are available
and administered."3 Statistics have shown that "18 million deaths per year

- 50 thousand daily-

are due to preventable poverty related causes...while one-third of the world's population subsists

on less than $2 per day and half of the world's population in some of the poorest countries in

Asia and Africa lack access to essential medicines."4 Globally, there has been a constant
struggle

in balancing intellectual property rights with human health and poverty reduction.

Crook reports that "the Joint LIN Program on HIV/AIDS estimates that between thirty-four and

forty-six million people around the world are living with the condition."
I Victoria E. Hopkins, Analysis of International Patent Protection and Global Public Health at 83,

http://www.princeton.edu/jpia/past-issues- 1 /2006/5.pdf.
2
Just Like My Child Foundation, HIV/AIDs at l. 2010.
3
Just Like My Child Foundation, HIV/AIDs at l.
a Hopkins at 85-86.

While sub-Saharan African states have suffered the worst epidemics to date, the World
Health Organization (WHO) predicts new outbreaks in North Africa, India, China, states in
Central Asia, and the Baltic states."5 Crook describes that "anti-retroviral drugs do not reach the

90% of HIV/AIDS infected people living in the poorest 10% of the world's countries. In South

Africa, tens ofthousands ofpeople are dying every year because excessive prices are charged for
life-saving antiretroviral medicines. The worst is probably yet to come for South Africa, where
lack ofaccess to effective medication will facilitate the rapid spread of AIDS-related deaths."6

In South Africa, the Medicines Act was established in order for actions to be taken in
order to promote public health

in times of

licensing. However, countries such

as the

severe need, such as allowing

for compulsory

United States have prevented this Act from being used

to accomplish its purpose.i For instance, the United States responded that the South Africa
Medicines Act would violate IP rights and impact the economy

by

adversely affecting

pharmaceutical companies.8 Hopkins states that "The heart of the debate is striking a balance
between the rights to IP protection, championed by multinationals and developed countries, and

the developing world's right to health via affordable drugs in the face of extreme disease and
poverty."e
The above outlined consequences of the prevailing policies regarding IP protection and
pharmaceuticals

is a result of a utilitarian economics approach. The utilitarian

economics

approach and the approach which pharmaceutical companies have expressed is that there is a
need for strong patent protection in order to generate profits which

5

will allow

pharmaceutical

Jamie Crook, Balancing Intellectual Property Protection with the Human Right to Health at 524.
Crook at 525.
7
Nagan, Intemational Intellectual Property, Access to Health Care, and Human Rights: South Afiica v. United
6

States. Florida lournal oflntemational Law at l'18.2002.
Nagan at 178.

8
e

Hopins at 84.

companies to further their research and innovation of medical drugs which

will consequently

be

better for global health. For instance, utilitarian economic theory is based on the belief that there

should be strong IP rights which are strongly enforced against those who infringe in order to
incentivize people to innovate.l0 Utilitarian economics is based on the premise that incentives

will allow for a high

amount

of social goods.ll The utilitarian approach is

premise that the creation and distribution

of

based upon the

effective pharmaceutical products requires

motivated individuals. In the absence of motivated individuals there

will

be no innovation and

widespread distribution of critical pharmaceutical products. Therefore, the public good

will not

be served. Utilitarians want to protect scientific innovation as they believe that a lack of
protection through the use of IP rights would cause there to be no incentive since others could
pirate their inventions and products and profit without actually creating
achieve the highest overall well-being and since pharmaceuticals

humans, IP rights and patents are necessary

it.l2 Utilitarians want to

will allow for the welfare of

to protect their inventions and products of

the

inventors.13 The evidence suggests however, that the continued policy of IP rights as manifested

in TRIPS does not result in the greatest good for the greatest number of people but even further
is unjust and therefore morally wrong. The utilitarian approach has been deemed unjust. This is
because

the struggle with poverty has continued to have devastating impacts due

to

pharmaceutical companies who have charged excessive prices and fail to allow generic drugs to
treat illnesses, including anti-retrovirals in order to treat HIV/AIDS.

An Alternative to Intellectual Property Theories of Locke and Utilitarian Economics, Michael Morrissey at 17,
http://etd.lsu.edu/docs/available/etd-07032012-160303/unrestricted/morrisseythesis.pdf.
lr Morrissey at 17.
12
The Clash between Global Justice and Pharmaceutical Patents: Cernea and Uszkai at215-216,
file:///C:/Users/morabima/Downloads/the-clash-between-global-justice-and-drug-patents-a-critical-analysis.pdf.
13
Cernea and Uszkai at215-216.
r0

The approach to IP rights and global pharmaceutical industry thus requires a different

philosophical, ethical framework.

I

would like to suggest a virtue and human flourishing

approach which is based on human good and well-being and helping others to also be able to

flourish by living ethical lives which parallels Nussbaum's capabilities approach, a virtue ethics

view.la Virtue ethics is an ethical system based upon adherence to a principle. Virtue ethicists
believe that there are "certain ideals toward which we should strive...[to allow] for the full
development of our humanity" by looking at what humans can become.ls The virtue ethicist
focuses on humans achieving their maximum potential while having virtues
generosity and courage.l6 For instance, "a person who has developed virtues

of

compassion,

will

be naturally

disposed to act in ways consistent with moral principles.lT Virtue ethics emphasizes character

formation and habits to foster positive improvements in the world.18 A virtuous person wants to
behave well and looks at a circumstance and decides what

is right and wishes to

behave

according to what is right.le This view aligns with Nussbaum who takes a capabilities view

which is based on the idea that well-being is "of vital moral importance [and]... individuals must
have real opportunities to live well and to flourish as human beings.20 Nussbaum's capabilities

view looks at the important functions of a human being and looks at what institutions are doing

for those capabilities.2r For example, functions and capabilities are set and then we

observe

whether intuitions are promoting human flourishing based on these principles.22 If the standards

Ia

Morrissey at 47.
Thinking Ethically: A Framework for Moral Decision Making, Manuel Velasquez at
http://www.scu.edu/ethics/practicing/decisioMhinkine.html/.
16
Velasquez at l.
17
A virtue ethics approach to moral dilemmas in medicine, P Gardiner at l,
http://jme.bmj.com/c ontentl 29 / 5 /297.1ong.
15

rE

re

20

Velasquez at 2.
Gardiner at l.

Morrissey at 47.
Morrissey at 47.
22
Morrissey at 48.
2r

l,

are not being met, we must try

to

change the institution's policies

to allow for human

flourishing.23 Nussbaum's capabilities approach explains what flourishing is and tries to achieve

this flourishing worldwide.2a Based on this theory, IP rights "generate a material circumstance
for a majority of the world in which we can't maximally exercise our intellectual capacities, and
thus we fail as a species to maximally flourish."25 Therefore any further discussion of IP rights
and the global pharmaceutical industry must proceed clearly focused on adherence to a moral

principle; maximizing human flourishing.
Successful efforts

in

South Africa were only achieved when the policy became

virtue/principle based. In the Minister of Health v. Treatment Action Campaign, the court ruled
that the government breached the people's right to have access to health care services when it

prevented drug availability

to

pregnant women

in

order

to stop mother-to-child HIV

transmission.26 2.4 million people have received free anti-retroviral treatment in 2013 which was
a 1.4 million increase from 2009 while over 20 million people have been tested for HIV since the
government created counseling and testing programs in2010.27 South Africa's goal is to have an

extra 4.6 million people receiving anti-retroviral treatment within the next five

years.28

Furthermore, South Africa has reduced the prices of anti-retrovirals and there was a tender to
make one ARV

pill which can be used once instead of having to take three pills two times per

day which means there

23

will be fewer pills

used and consumed.2e Although there have been

Morrissey at 48.
Morrissey at 48.
25
Morrissey at 48.
26
Zivi at 180.
27
SA to expand HIV treatment program, 2014 at l,
http://www.southafrica.info/about/government/stateofrtation20l4e.htm#.UwN24P6A0eE.
28
SA to expand HIV treatment program at L
2e
South Africa's savings in procurement of antiretroviral drugs at 1,2012,
http://www.unaids.org/enlresources/presscentre/featurestories/2012lnovember/20l21l3Dzatreatmentprices/.
2a

successes,

the South African population continues to have the highest number of HIV/AIDS

infected people globally as millions still lack access to ARVs.30

The ongoing tension between the fight against poverty and IP rights continues to persist

at the mercy of humans in poorer nations who are unable to afford medications to cure their
illnesses and diseases which hinders maximum human flourishing and does not express good

character. In her article "Common Ground: The Case for Collaboration Between Anti-Poverty
Advocates and Public Interest Intellectual Property Advocates" Cantrell states that with
intellectual property advocates, their focus is on the individuals rights to create, appropriate, and

recreate.3l However, the tension between the fight against poverty and the protection of
intellectual property rights is evident as the IP movement's success is frequently at the expense

of the poor.32 Cantrell continues to state that Martha Nussbaum's virtue theory of

human

capabilities suggests that every person should have the ability to live a flourishing life yet the IP
movement has placed limitations on what a person can do and be as a result

of

continued

poverty.33

Advocates of the anti-poverty movement have placed significant emphasis on the United

Nations Commission on Human Rights which has determined that access to medicine is a human
right.3a However, pharmaceutical companies have a great amount of control over the distribution
and prices of medications. For instance, the World Trade Organization implemented TRIPS, an

intemational treaty regarding intellectual property rights standards

in order to allow for

IP

protection.35 The idea behind the TRIPS treaty was to give pharmaceutical companies an

30

7.ivi at 182.
I. Cantrell, Common Ground: The Case for Collaboration Between Anti-Poverty Advocates and Public
Interest Intellectual Property Advocates, Spring 2008 at 423.
32
Cantrell at 423.
13
Cantrell at 428.
3a
Universal Declaration ofHuman Rights, available at http://www.un.org/Overview/rights.html.
35
Crook at 530.
3r Deborah

incentive to invent medications while being able to profit from the creation of pharmaceutical

drugs. TRIPS provides for patent protection for twenty years from the time of
Proponents

of

filing.36

intellectual property rights including intellectual property specialist Gerald

Mossinghoff have explained

:

"Effective patent protection at home and abroad is vitally important to the United States
pharmaceutical industry. America's research-based pharmaceutical companies pour millions

of new technology every year.

dollars into the research and development

of

Whether this

commitment can continue depends greatly upon the extent to which foreign govemments allow
innovators to be rewarded for their inventiveness, monetary investment, and intellectual labor.

For the private sector pharmaceutical industry, which has been the primary source of new
therapies

for the past four

decades, there

is little incentive to provide an ever-increasing

commitment to research unless there are reasonable expectations of financial retum. Only
effective patent protection provides the incentives necessary to enable pharmaceutical companies
to commit the required resources."

IP rights proponents have argued that protection is essential for incentives to

create.37

Furthermore, Hopkins explains additional arguments in favor of IP protection are the incentives
due to the financial rewards as a lack of patents would make

it hard for creators to recover their

investments due to reverse engineering and knock offs which would result in fewer investments
and less research to treat worldwide diseases.3s

However, this patent protection inflates prices more than one hundred times their cost

which hinders humans worldwide fiom opportunity and from being able to have well-being so

36

Lazzarini at 109.

37

Fisher and Syed at 6?2.
Hopkins at 85.

38

that they may flourish.3e
companies, especially

It is

significant to note the political power that pharmaceutical

in the United

States, where lobbyists contributed millions annually.

Although innovators should be rewarded, pharmaceutical companies should shift their focus to
poorer nations in order to limit the spread of disease, allow those in poverty right to life and
result in more trading partners by having a pricing scheme based on per capita income in order to

allow medications and treatments to be available to poorer populations.

II. THE PROBLEM WITH DRUG INNOVATION
As pharmaceutical companies continue to invent drugs and medications there has been a
continued focus on the rich which does not allow for maximum human flourishing as many
people are left without access to essential medicines. Pharmaceutical companies have focused

on the needs and wants of those living in wealthy companies while forgetting about those in
poorer nations. For instance, Sunder states that "The dominant law-and-economics approach
would rely on the market to spur creation but this leads to the appalling conclusion that drugs for
baldness must be more important than drugs

for malaria because the former enjoy a multi-

billion-dollar market, while those who need the latter are too poor to offer much to save their
own lives" as the focus of pharmaceutical companies has been on developing lifestyle drugs.

a0

This is because companies have more of an incentive to innovate where tlere is a wealthier
market with the ability to pay as this will result in the highest profits. Those in poorer nations
are more

likely to have illness and death than those living in wealthier nations while 95% ofthe

people who have

HIV reside in developing nations.al Moreover, according to the United

Nations Joint Programme on AIDS, lack of access to treatment has resulted in decreased survival

re

Crook at 533.
Madhavi Sunder, From Goods to a G ood Life at29,2012.
4t Zita Lazzarini, Making
Access to Pharmaceuticals a Reality: Legal Options Under TRIPS and the Case ofBrazil
at 105-106.
40

rates across poorer nations.42 Additionally, the inflated drug prices have caused poor nations to

be unable to afford treatment and drugs due to their significant mark

that only

4.3%o

of

research and development

up.

Statistics have shown

for health was geared to the needs of poorer

nations.al Hopkins notes that:

"While developing countries form 80 percent ofthe market, new research is predominantly spent
on rich country concems... Tuberculosis, malaria, pneumonia and diarrhea account for 20 percent

of world disease and are rampant in underdeveloped regions of the world but obtained less than

1

percent ofthe funds allocated to health research in 2002...Developed countries should recognize
the role they have in ensuring that all individuals can exercise the right to public health no matter

their geographical or economic location. Signatories to the UDHR declaration have

an

obligation to protect those beyond their own border. A global movement to shift the R&D focus
beyond the bottom line figures is necessary so as to incorporate neglected developing world
diseases."aa

Lazzaini notes that although high prices prevent poorer nations from access to
medications and other treatment, there are also numerous other barriers.as For instance, she
explains that the lack of public infrastructure is yet another barrier as there is a lack of testing,

counseling and overlooking

of

diseases.a6 She further notes that developing nations lack

clinicians and facilities who have the training and education necessary to give anti-retroviral
treatment and check on the progress of the patients.aT An improved infrastructure

a2
a3

Lazzarini al106.
Barry and Raworth, Access to Medicines and the Rhetoric of Responsibility. Ethics and lntemational Affairs at

57 .2002.
a Hopkins at l0l.
45

46
47

will allow for

Lazzarini at ll4.
Lazzar],:,i at I | 4.
L?,Zar]Ji,i al

ll4.

more doctors and better clinicians and facilities providing access and treatment so that humans
infected with

HMAIDS

have the opportunity to flourish.

Although there have been numerous developments and much progress with drug
inventions, the needs ofthe poorer nations have often been overlooked while the focus has been
on wealthier nations. This poses significant issues as the majority of poverty and illnesses lie in

the nations were pharmaceutical companies failed to aim their focus. For instance, Fisher and

Syed state

in an article entitled, "Global Justice in

Healthcare: Developing Drugs

for

the

Developing World" that "pharmaceutical firms concentrate their research and development
resources on diseases prevalent in Europe, the United States, and Japan

receive 90-95Yo of their revenues

-

and most of the diseases that

-

areas

from which they

afflict developing countries

are

uncommon in those regions."48 Statistics have shown that "neglected diseases account for 16.40%

of the global disease burden. Yet, the portion ofglobal R & D expenditures that is comprised
research directed at those diseases is in the range of 2-3%o.

of

Only 1.5% of the total global burden

takes place in the developed world, where the pharmaceutical firms earn roughly 95% of their
revenue."4e Fisher and Syed have suggested that the amount of money spent on R&D should be
increased

in the areas of medications and treatments for neglected

diseases

by using more

resources or by using some of the funds that are now being used on non-neglected diseases.50

This value based approach will allow for human beings globally to live healthier lives in order to
live to their best capabilities.

III. POVERTY AND ITS CONCERN
A. STOPPING THE SPREAD OF DISEASE
48

Fisher & Syed, Global Justice in Healthcare: Developing Drugs for the Developing World at 585, March 10,
2006. http://laweyiew.law.ucdavis.edu/issues/40/3/developing-drugs-for-developing-

word,/DavisVol40No3_Fisher.pdf.
4e
50

Fisher and Syed at 612.
Fisher and Syed at 612-613.

Many of the diseases that affect poorer nations are excruciating both to those infected and
the family members where it is accepted that the likelihood of treatment and medication is slim
as these humans lack opportunity and well-being. However, these diseases also impact others

who may come into contact with infected individuals. In the article "Global Health Govemance"
the authors state that "Globalization has introduced or intensified national borders in their origin

or impact. Such risks may include emerging and reemerging infectious

diseases, various

noncommunicable diseases (e.g. lung cancer, obesity, hypertension)."5r It is critical to note how

quickly illnesses spread impacting the entire community. Crook states that greater access to
medicine

will allow for political, social and economic

structures to be more stable in poor

nations and there should be focus on prevention and treatment of diseases.52 Fisher and Syed
state that there are negative extemalities with these diseases that stretch beyond the infected

individuals since those around them have a higher chance of getting the illness as well
outbreaks need supra-national cooperative

as

action.s3 Thus, we should strive for the full

development of humanity.

B. INCREASED TRADE AND MORE TRADING PARTNERS

Shifting the focus of pharmaceutical companies on the needs of poorer nations will not

only improve health and prevent the spread of disease yet it will also help promote economic
development by increased trade and allowing for a rise in the number of trading partners due to
an improvement in human

flourishing. Fisher and Syed have explained that trade will help both

the North and the South as there

51

will be more

markets and more productivity with trading

Ri"h*d Dodgron, Kelley Lee and Nick Drager, Global Health Governance at 7, February 2002,
http://cgch.lshtm.ac. uk/globalhealthgovemance.pdf.
52
Crook at 538.
53
Fisher & Syed at 588-589.

partners as there are great links between increased health

will

ofa nation and its development which

also decrease chances of instability.s4

As

diseases spread, the

impacted by these diseases

life

expectancies

in

poorer countries that are significantly

will likely decline. This decline in life

expectancies

will certainly

affect labor and the ability to produce and trade goods. However, allowing poorer nations to
have access to medication and life-saving treatments while save lives allowing countries and its

citizens to be more productive being able to work and produce goods, and this

will maximize

flourishing for citizens ofrich countries as well.
C. THE RIGHT TO LIFE
There is a right to life which includes a right to medication in intemational law as well as

in the South African Constitution and is consistent with a virtue ethics approach in promoting
maximum human flourishing globally. Although intemational law documents and treaties do not
specifically state that there is a right to pharmaceuticals, this right is founded in "the implications

of

existing substantive provisions and

in the

special needs created

by the

curent

circumstances."ss For instance, the Universal Declaration of Human Rights states that there is a

"right to life, liberty and security of person... [and] no one shall arbitrarily be deprived of his
life."56 The Universal Declaration of Human fughts also establishes "the right to a standard of

living adequate for health and well-being of himself and his family [which] includes medical
care and necessary social services, and the right to security in... sickness, disability, widowhood,

old age or other lack of livelihood in circumstance beyond his control" as the UDHR has been
considered customary intemational law.57 The Intemational Covenant on Economic, Social, and

t4 Fisher and
Syed at 589-590.
55

Lazzarini at 1l't .
Universal Declaration ofHuman Rights, art.3.
57
Universal Declaration ofHuman Rights, pmbl. 1948.
56

Cultural Rights (ICESCR) states in Article 12 that there is a right to "the highest attainable
standard

of physical and mental health" requiring states to ensure for "the provision for the

reduction of the stillbirth-rate and of infant mortality and for the healthy development of the

child, the improvement of all aspects of environmental and industrial hygiene, the prevention,
treatment and control of epidemic, endemic occupational and other disease [and] the creation

of

conditions which would assure to all medical service and medical attention in the event of
sickness."s8 Continually, the ICESCR creates the right to "enjoy the benefits of scientific
progress."se Moreover, the WTO requires the right of "enjoyment of the highest attainable
standard of health" which is considered 1o be a "fundamental right ofevery human being without

distinction ofrace, religion, political belief, economic or social condition."60
Crook states that the Committee on Economic, Social, and Cultural Rights discusses the

right to health in Article 15 which "recognizes the right of everyone to enjoy the benefits of
scientific progress and its applications and to benefit from the protection of the moral and
material interests resulting from any scientific, literary or artistic production of which he is the

author" "which could include access to break-through medications."6l Moreover, under the
Intemational Covenant on Civil and Political Rights (ICCPR), Article 6(1) states that "Every
human being has the inherent right to

life. This right

shall be protected by law. No one shall be

arbitrarily deprived ofhis life."62 This provision can be interpreted

of

access

as the

right to life consisting

to medication to allow for cure and prevent death from an illness that can be cured

through prescriptions. Another example of intemational law which requires a right to medication

58

lntemational Covenant on Economic, Social, and Cultural Rights, art. 12.1, C.A. Res.2200A(XXI) U.N. GAOR,
Supp. No. 16, at 49,1966.
5e
/d., art. 15 $ l, !l b.
60
Constitution ofthe World Health organization, 1946.
6r
Crook at 535.
62 International Covenant on Civil and Political Rights Art. 6(l), March 23, 1976.

i.,.tua", the Convention on Rights of the Child which states in Article 6 that "State parties
recognize that every child has the inherent right

to

life.

States parties shall ensure

to the

maximum extent possible the survival and development of the child."63 The aforementioned
treaties and customary international law express the right to life which is often at risk as a result

of

intellectual property protection. As explained by Audrey Chapman, the human rights

approach focuses on protecting human dignity while balancing inventors interests which are
conditioned on assisting society's welfare.@

In addition to the right to life as expressed in international law (treaties and customary
international law), this right is also evident in domestic law such as in national constitutions. For
instance, our very own U.S. Constitution provides in the 14ft Amendment that "nor shall any

state deprive any person
Constitution, Article

of life, liberty, or property."65

1l provides

Moreover,

in the South African

that "Everyone has the right to life."66 The South African

Constitution requires the government to take reasonable measures to allow for the right to access
health care services.6T The existence and application of a right to life is an example of a virtue
ethics approach which exists and works. The right to life encompassed in the constitutions

of

various domestic nations demonstrates the right to access to pharmaceuticals in order to allow a
person to be treated and continue to live as individuals should be allowed to live well.

IV.

RECOMMENDATIONS

TO BETTER BALANCE PUBLIC HEALTH AND

INTELLECTUAL PROPERTY RIGHTS

63covenant

on the Rights of the Child, Nov. 20, 1989, art. 6.
Audrey R. Chapman, Approaching Intellectual Property as a Human Right: Obligations Related to Article l5
(c) at note 61.
6a

65

U.S. Const. Art. XIV.
South Africa Const. Art. XI.
67
Fix the patent laws at 3, http://www.tac.org.zalcommunitv/node/3241.
66

(l)

There have been some successful efforts to reduce poverty by permitting access to
medication which has focused on maximizing well-being. Cantrell points out that

in

South

Africa, Bristol-Meyers "agreed not to enforce a patent on an important AIDS/HIV medication,
permitting the South African govemment to purchase a lower-priced generic version."68 The
Millennium Development Goals were established to decrease poverty as part of the Millennium
Declaration.6e The Millennium Declaration was signed in September 2000 by 189 countries.T0

One of the United Nations Millennium Development Goals was to halve the people whose
income was under $1.25 aday in the years 1990 and20l5.7r The goal of halving the poverty
rates was met

five years before the 2015 deadline.T2 In 2010, 700 million fewer people lived in

conditions of extreme poverty compared to in 1990.73

Unfortunately,1.2 billion people still live in poverty on a global scale and we must strive
for the full development of humanity.Ta Another United Nations Millennium Development Goal
was to cut the proportion of people who are undernourished by half by 2015.7s Across the world,

approximately 870 million people are malnourished while over 100 million children below five
years old are malnourished and underweight.T6 Krishnan states that "Millennium Development
Goals relating to HIV, tuberculosis and malaria, there were to have halted by 2015 and began to

reverse" and "according to the 2013 report, HIV remains the leading cause of death for women
of reproductive age globally with one woman dying every minute."77

68

Cantrell, at 437.
Vidya Krishnan, Countries meet poverty reduction goal, but trip on maternal health, July 4, 2013 at l.
70
lGishnan at l.
7r United Nations Millennium Development Goals at 1, http://www.un.org/millenniumgoals/poverty.shtml.
72
United Nations Millennium Development Goals at 1.
73
United Nations Millennium Development Goals at 1.
74
United Nations Millennium Development Goals at l.
7s
United Nations Millennium Development Goals at 1.
76
United Nations Millennium Development Goals at l.
77
Krishnan at 2.

6e

The purpose ofTRIPS is "reducing distortions and impediments to intemational trade and
ensuring that measures and procedures to enforce intellectual property rights do not themselves

become barriers

to legitimate trade."7s However, intellectual property rights have become

barriers to trade especially in relation to poorer countries receiving access to medications and
treatments. Although the first line ARVs have declined in price from $10,000 per patient to $60
per patient there are only

4%o

of people with second line ARV medications as 147o are needed

and the cost is 2.5 more expensive than the first ARV medications while the third line of ARV

drugs are lacking.ie The prices for the ARV medications are up to 35 times the amount of
nations who have greater generic competition.8o This lack of access hinders the achievement

of

maximum human flourishing and there should be a focus on humans achieving their highest
potential.

Patent protection needs

to be relaxed which will permit generic medications

through

compulsory licenses and make treatment affordable to poorer nations which would allow for an
increase in human flourishing.8r At the same time, IP rights do need to be protected to the extent

necessary

to sustain the "human flourishing" of the pharmaceutical companies. Compulsory

licensing has been defined by the WTO under TRIPS as follows: "when a govemment allows
someone else to produce the patented product or process without the consent

It is one of the flexibilities on patent protection included in the TRIPS

ofthe patent owner.

agreement."82 The WTO

continues to explain that these flexibilities have been incorporated into TRIPS since its adoption

78
7e

Lazzarini at 109.

South Africa: Activists urge change to patent laws at 1, http://www.irinnews.or{report/94272lsouth-al}icaactivists-urge-change-to-patent-laws.
80
In WHO, South defends use of TRTPS flexibilities for public health at l,
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in January 2005.83 Furthermore, the WTO states that for compulsory licensing to be applicable
there does not necessarily need to be an emergency as countries may determine when to grant
compulsory licenses.Ea

In clarifying numerous questions regarding compulsory licensing under TRIPS the WTO
explains:

"The TRIPS Agreement does list a number of conditions for issuing compulsory licenses, in
Article 31. In particular:

o

Normally the person or company applying for a license has to have tried to negotiate a
voluntary license with the patent holder on reasonable commercial terms. Only

if

that

fails can a compulsory license be issued, and

.

Even when a compulsory license has been issued, the patent owner has to receive

payment; the TRIPS Agreement says "the right holder shall be paid adequate
remuneration in the circumstances of each case, taking to account the economic value

of

the authorization" but it does not define "adequate remuneration" or "economic value."

It cannot be given exclusively to licensees (e.g. the patent holder can continue to produce), and it
should be subject to legal review in the country."85

Additionally, TRIPS states that for "national emergencies", "other circumstances of
extreme urgency" or "public non-commercial use" (or "govemment use") or "anti-competitive

practices", a voluntary license is not required as this step can be skipped when time is crucial,
however; the patent owner must still be compensated.86 Adequate compensation is determined

World Trade Organization, Compulsory licensing of pharmaceuticals at l.
World Trade Organization, Compulsory licensing of pharmaceuticals at 1.
85
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83
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by officials in the concemed country while the patent owner may appeal.87 The TRIPS
agreement in Article

3l

had previously stated that compulsory licenses were to be given for the

domestic market.88 However, at the Doha Conference in 2001, this provision was changed to

allow nations who were unable to create the pharmaceuticals to be able to get them at a lower
price from somewhere else if needed.8e The purpose of changing this provision was to create a

way to "allow generic copies made under compulsory licenses to be exported to countries that
lack production capacity" which will allow for well-being.eo

Similarly, according to the IP unit and members of the University of KwaZulu-Natal,
South Africa can specifically focus on generic medications

in order to foster flourishing.

elFurthermore, compulsory licenses are not limited to emergencies
and can be issued ifthere is a
shortage in supply to the market, "a desire to make fixed-dose combinations of medicines owned

by different right holders, dependent patent that is technologically important, desire to

have

multiple sources of supply to prevent shortfalls of stock, and even a desire to promote local
production where there have been failures in technology transfer from right holders."e2 A focus
on generics will allow for human good and will allow individuals to live well.

Twenty-three nations have decided that they would not use compulsory licensing in
importing including: "Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany,

Greece, Iceland, Ireland, Italy, Japan, Luxembourg, Netherlands, New Zealand, Norway,
Portugal, Spain, Sweden, Switzerland, United Kingdom and the US. Since they joined the EU,

the list now includes 10 more: Czech Republic, Cyprus, Estonia, Hungary, Latvia, Lithuania,
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Malta, Poland, Slovak Republic and Slovenia."e3 Eleven other nations have stated that they

would only use compulsory licenses

if

there is a national emergency or "extreme urgency"

including: Hong Kong China, Israel, Korea, Kuwait, Macao China, Mexico, Qatar, Singapore,
Chinese Taipei, Turkey, and United Arab Emirates. While it is known that twenty-three nations

will not use compulsory licensing for importing

and eleven others agreed only to use compulsory

licensing in extreme emergencies, it is evident that compulsory licenses for pharmaceuticals have
received serious criticism as interfering with intellectual property rights of the inventor. The

WTO stresses that all of the obstacles have not been removed as in order to use compulsory
licensing, exporting countries must also modiff their laws so that they are consistent with the
modifications made under TRIPS rather than simply allowing compulsory licensing mainly for

their domestic use.ea Presently, Norway, Canada, India and the EU have modified their laws to
be consistent with the changes under TRIPS.e5

In

1965, South Africa realizing that the IP laws at the time were not conducive to

flourishing, amended the Medicines Act in order to increase availability of medicines which has

been an effort towards improving well-being.e6 The nation's office for patents

is in

the

Companies and IP Commission which was created by the Companies Act and is responsible for

registering the patents.eT However, patent applications are not thoroughly examined.es The

Court for patents is the Commissioner of Patents who has authority under the Patents Act to
make rulings regarding infringements and compulsory licenses.ee Patents are maintained in the

e3
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Patent Joumal that is now available electronically.loo Under the Patents Act, the process for

compulsory licensing is both long and expensive and must be brought before the Commissioner

in a judicial proceeding which can take three or even more years as the

process has been

criticized for being unclear as the application goes to the commissioner, the judge of the High

in high costs due to

Court which results

arguments, adjoumments and undue delays.lol

However, TRIPS does not require the strict requirements adopted by South Africa in order to

obtain a compulsory license.ro2

It

has been suggested that specific standards should be

implemented in order to help the Commissioner when deciding what is considered adequate in
terms of remuneration in order to avoid long litigation and high costs.lo3 By allowing for more

specificity

in

standards

for compulsory licenses, generic companies will be able to

better

"negotiate voluntary licenses on reasonable terms", produce more and provide greater access.lM
For instance, Canada caps the royalty rate to be 4Vo of the generic product's price.r05 According

to the United Nations Development Programme, "there may be cases in which the issuance of a
compulsory license is not a sufficient remedy for certain anti-competitive practices" and in those
cases patents should be able

to be revoked in order to prevent abuses. 106

Presently, a

compulsory license for generic versions of the third line ARV is in dire need as there are no
generics for the third line of treatment currently available.r0T

Another suggestion is to allow parallel imports to allow for human good by wider access

to medicines. Parallel imports are defined by the World Health Organization as "imports of a
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patented or trademarked product from a country where

it is already marketed."lo8 The World

Health Organization provides examples ofparallel importing and also explains the consequences
that will result from parallel importing as follows:

"In Mozambique 100 units of Bayer's ciprofloxacin (500mg) costs US$740, but in India
Bayer sells the same drug for US$15 (owing to local generic competition). Mozambique can
import the product from India without Bayer's consent. According to the theory of exhaustion of

intellectual property rights, the exclusive right of the patent holder to import the protected
product is exhausted, and thus ends, when the product is first launched on the market. When a
state or group of states applies this principle of exhaustion of intellectual property rights in a
given territory, parallel importation is authorized to all residents in the state in question. In a state

that does not recognize this principle, however, only the patent holder who has been registered
has the right

to import the protected product... Parallel imports often takes place when there is

differential pricing of the same product

-

either brand-name or generic drugs

- in

different

markets (usually owing to local manufacturing costs or market conditions)... Parallel imports

can reduce the price

of

health products and pharmaceuticals

by introducing

competition.

However, they can also affect the negotiation of tiered pricing regimes with pharmaceutical
companies.

Ifa private

countries, it

will

pharmaceutical company agrees to sell a product at a lower price in poor

need some assurance that the cheaper product

will not be imported back into its

rich country markets, undercutting its profits (product diversion)."r0e

Hopkins writes that parallel importing "[with] generic phamaceuticals, [has allowed]
members of Kenya's non-profit sector [to] successfully lower the cost of anti-retroviral triple

r08
r@

World Health Organization, Parallel lmports at l, http://www.who.invtrade/glossary/story070len].
World Health organization, Parallel lmports at 1 .

therapy drugs by 40%-65%...[ias parallel importing] endorses price equity in the market."rr0 As
pointed out by the World Health Organization if parallel importing is permitted, pharmaceutical
companies will be less likely to agree to tiered pricing which is another altemative. For instance,

Crook suggests that there should be different pricing structures according to a formula for
countries based on their per capita income, resources and the necessity for instantaneous
medication.l

rr

The strategy of pricing structures means that there would be price discrimination

in that pharmaceutical companies would offer medications at lower prices in some nations while
being able to keep higher prices in other nations.rr2 A pricing structure is not currently in place
as

all countries must pay the same inflated price preventing poorer nations from having access to

treat diseases. For instance, Fisher and Syed have promoted changes to laws based on the
distribution of pharmaceutical innovations by allowing more governmental control over the
prices set for the medications while also allowing govemments to oversee how pharmaceutical
companies choose to invest and focus their research and development.ll3 For them, greater
govemmental control means greater access.

In South Africa, under the Minister of Health v. Treatment Action Campaign, it was ruled

in2002 that health care services consist of

access

to medicines.lla According to the wording of

the South African Constitution, the govemment must adopt a legal framework 10 allow for access

to essential medicines but also to take action in order to allow for a decline in drug prices in the
private sector while making sure that there is an adequate supply of the medication which may
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include direct price controls.rls Allowing for an adequate supply of medication through price

controls is consistent with allowing for human good. The govemment can implement direct

price controls by creating state guidelines for price-setting to allow manufacturers to create
prices and state factors to be relevant in setting prices.l16 Furthermore, the govemment can enact

legislation which prohibits high prices or can set direct price controls capping prices.

r17

Another suggestion has been to provide public funding such as govemment subsidies in
order to help pharmaceutical companies by allowing them to have funds for continued research
and development in order to continue with medication developments.r

r8 By implementing the

aforementioned suggestions, t}re concems of proponents of intellectual property rights vrill be
addressed since inventors

will still be able to enjoy the "fruits of their labor" but would be

prevented from charging extremely inflated prices. This would allow poorer nations to be able to
purchase medications and treatments as pharmaceutical companies would also look to address

the concems and needs of poorer nations suffering from diseases while focusing their research
and development on these concems.l

19

Additionally, the Department of Trade and Industry suggested on September 4, 2013 that
South Africa can have national policies such as taxes on medicines to promote well-being.l2o A

further suggestion is to enact legislation to limit patents while allowing for generics in order to
promote competition in order to allow for lower prices.l2l The Department has also suggested

that distribution and manufacturing capacities be improved.
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crurent issue in South Africa is that the nation does not thoroughly look at patent applications
and allows for companies to have numerous patents on the same medication even

if they do not

qualifu as an "innovation" by definition which results in corporations to "extend the life of their

monopolies, block competition from generic manufacturers and charge inflated prices for
medicines in both the public and private sector."l23 Another suggestion by the Department is
that a solution would be to create a more strict definition for innovation and not allow patents

when current medications are combined or allowing patents for new uses of the patented
drugs.l2a In other words, South Africa should not grant patents for existing medications that
have very small chemical changes. Other recommendations

in at a WHO Executive Board

Meeting in January 2014 ina Draft Resolution included limiting patents to only 20 years, having

a more thorough examination process for patents and focusing on parallel importation

and

compulsory licenses.l2s South Africa grants numerous patents as 2,442 palents were granted in

2008 alone while countries such as Brazil only granted 278 patents from 2003'2008.t26
Furthermore, applying for patents is twenty times cheaper than the majority of patent offrces as

South Africa lacks a thorough patent examination process as this simplicity allows for more
patents and less access to medications due to the approved patents hindering humans from
achieving maximum potential by preventing individuals from living well with the ability to have
medicines.l2T

Further, the Department of Trade and Industry suggests this system could provide for
specific legislation to allow a right to healthcare under the South African Constitution.r28 The
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South African govemment has provided for the anti-retroviral treatment while also providing
counseling and testing which has had success.l2e South African President Ztma stated that

l0

new hospitals were build or renovated and that the nation would begin "a new phase in the
implementation

of the National

healthcare to the poor...[as there

Health Insurance progftlmme, which

will

extend quality

will also be] construction of 300 new health facilities, including

160 new clinics" as efforts to decrease the number of people with

Another suggestion is that

HIV/AIDS in South Africa.l30

in order to shift the focus of

pharmaceutical companies

towards the needs of poorer nations, developed nations should create public-private partnerships

amongst pharmaceutical companies and governments

in

order

to promote research and

development towards world diseases.l3l Public-private partnerships "would be based on
mechanisms of incentives where governments agree to purchase developed vaccines from firms
at a pre-negotiated price upon development, focusing on medicines in developing countries such
as malaria vaccines."l32

The eighth Millennium Development Goal was to create a global partnership for
development.r33 The World Health Organization stated the goal was

to work with

pharmaceutical companies to allow for access to "affordable essential medicines in developing

countries."l3a 16" WHO reported that:

"Although nearly all countries publish an essential medicines list, the availability of medicines at
public-health facilities is often poor. Surveys conducted in over 50 low- and middle-income
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countries indicate that the availability of selected generic medicines at health facilities was only
38% in the public sector and 64% in the private sector. Lack of medicines in the public sector
forces patients to purchase medicines privately. In the private sector, generic medicines cost on
average six times more than their intemational reference price, while originator brands are

generally even more expensive. High prices often make medicines unaffordable, with common
treatments costing the lowest paid govemment worker several days' wages."l35

Furthermore, the WHO's approach in creating a global partnership for access to essential
medications includes certain activities such as:

.
.

"WHO has developed global indicators for availability, price and affordability of
essential medicines.

WHO/Health Action International pricing survey metlodology used in over 50 countries
ofthe pricing, affordability and availability of branded and
generic medicines in the public and private sectors.
WHO provides pharmaceutical manufacturers with the information they need to produce
quality, safe, effective essential medicines to address leading public health concems.
WHO offers essential capacity building and quality assurance monitoring for over 250
medicines to treat millions of patients with HIV/AIDS, tuberculosis and malaria, and with
reproductive health needs in developing countries."r36

has increased awareness

.
.

Additionally, it is impo(ant that state and non-state actors are both involved in order to
achieve global justice with access to medication and treatment. According to Dodgson, Lee and

Drager, "liberal-intemationalist scholars view the purpose of global govemance as ultimately

moving towards a more liberal democratic global order in which states and IGOs have equal
roles.l37 Within such an order it is envisaged that power and influence will flow in a top-down

manner."l38 Continually, cosmopolitan democrats are proponents of diverse people within a
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collaborative political community including IGOs and a larger intemational legal system.l3e
Despite the numerous approaches to global govemance, there is a need for a global framework as
suggested by Dodgson, Lee and Drager

it is essential to establish leadership and authority with

health govemance globally as there must be sufficient resources "for health cooperation" as the
resources must be "distributed appropriately according to agreed priorities."lao These priorities

should be based upon the principle maximization of human flourishing.

V. CONCLUSION
Pharmaceutical companies have a tremendous impact on the global access to medicine.
Oftentimes, the focus of pharmaceutical companies is on the wants of the richer nations in order

to increase their profits. However, this has led to lack of access to medication in poorer nations
where humans have suffered and died as a result of lack of access to medications and treatments.

Pharmaceutical companies, govemments and international trade organizations have largely
maintained policies regarding IP rights which are based upon utilitarian economics. In other
words, they have promoted and sustained policies which purport to provide the greatest good to
the greatest number of people. The evidence outlined above shows that these policies do not

work this way. Indeed, in order to fulfill the utilitarian goal it must be scraped. The more
effective approach as outlined above is a virtue ethics one with a focus on striving for the full
development of humanity in order to allow for a human good. An example of this is the right to

life law which has been provided for in many international law treaties as well as intemational
customary

law.

This right includes the right to access to medications which will allow

individuals to live well. Some suggestions for allowing access to medication to poorer nations in

dire need of these treatments include compulsory licenses, public funding as well as a tiered139
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which would make medications accessible to poorer nations while still providing

for intellectual property protection and revenues for pharmaceutical companies. Access to
medication to poorer nations will help prevent the spread of diseases in those nations and across
the globe and

will

at the same time be beneficially to the economy in that poorer nations

able to trade with other nations allowing for more products and trading

will

be

partners. Pharmaceutical

companies should focus their resources and research and development more towards these poorer
nations in order to reduce illnesses in those nations as ethics require which will allow for humans
achieving their maximum potential.lal
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